Home
NICE Guidance
Conditions and diseases
Blood and immune system conditions
Blood conditions
Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate
Evidence summary [ESUOM4]
Published:
29 January 2013
Advice
Information for the public
Key points from the evidence
Overview for healthcare professionals
Relevance to NICE guidance programmes
Intervention and alternatives
Evidence review: efficacy
Evidence: safety
Evidence: economic issues
Evidence strengths and limitations
Summary for patients
References
Changes after publication
Development of this evidence summary
Appendix: Search strategy and evidence selection
About 'Evidence summaries: unlicensed or off-label medicines'
Download (PDF)
Advice
Next
Changes after publication
Changes after publication
July 2015:
Minor maintenance.